癌診療指針のための病理診断プラクティス　原発不明癌

出版社： 中山書店
著者：
発行日： 2019-11-20
分野： 基礎医学  >  病理学
ISBN： 9784521747866
シリーズ： 癌診療指針のための病理診断プラクティス
電子書籍版： 2019-11-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

22,000 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

22,000 円(税込)

購入する

商品紹介

原発巣が不明なまま見つかる「原発不明癌」は，予後不良の癌として，これまであまり顧みられることがなかった．
しかし，個別化医療の時代を迎え，分子標的薬の出現もあり，原発不明癌の治療の可能性がみえてきている．
本書では各臓器別に原発不明癌の原発巣探索の方法を分析し，治療への道しるべを解説する．病理医だけでなく臨床医や腫瘍内科医にもお勧めです．

目次

  • 1章　序論
    2章　基本的知識
    3章　探索法の実際
    4章　原発不明癌の背景―転移部位別の探索の実際
    5章　治療法の選択
    6章　症例提示
    7章　免疫組織化学抗体一覧表

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 序論

P.2 掲載の参考文献
Monzon FA, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue origin. J Clin Oncol 2009 ; 27 : 2503-8.
PubMed
Pavlidis N, et al. Cancer of unknown primary site. Lancet 2012 ; 379 : 1428-35.
PubMed
Tan DS, et al. Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol 2013 ; 31 : e237-9.
PubMed
Varadhachary GR, et al. Cancer of unknown primary site. N Engl J Med 2014 ; 371 : 757-65.
PubMed
Ross JS, et al. Comprehensive genomic profiling of carcinoma of unknown primary site : New routes to targeted therapies. JAMA Oncol 2015 ; 1 : 40-9.
PubMed
Varadhachary G. Carcinoma of unknown primary site : The poster child for personalized medicine? JAMA Oncol 2015 ; 1 : 19-21.
 
Bussu F, et al. HPV and EBV infections in neck metastases from occult primary squamous cell carcinoma : another virus-related neoplastic disease in the head and neck region. Ann Surg Oncol 2015 ; 22 Suppl 3 : S979-84.
 
Honda A, et al. Successful control of carcinoma of unknown primary with axitinib, a novel molecular-targeted agent : a case report. Chemotherapy 2014 ; 60 : 342-5.
PubMed
Galloway TJ, et al. Management of squamous cancer metastatic to cervical nodes with an unknown primary site. J Clin Oncol 2015 ; 33 : 3328-37.
 
Boscolo-Rizzo P, et al. The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes : a systematic review. Clin Exp Metastasis 2015 ; 32 : 835-45.
PubMed
Conner JR, et al. Metastatic carcinoma of unknown primary : diagnostic approach using immunohistochemistry. Adv Anat Pathol 2015 ; 22 : 149-67.
PubMed
Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015 ; 373 : 737-46.
PubMed
日本臨床腫瘍学会編. 原発不明がん診療ガイドライン 2010年版. 東京 : メディカルレビュー社 ; 2010.
 
向井博文. 原発不明がん―適切な診断・治療のポイント. 東京 : メジカルビュー社 ; 2012.
 

2章 基本的知識

P.6 掲載の参考文献
NCCN guideline. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf
 
Pavlidis N, et al. Cancer of unknown primary site. Lancet 2012 ; 379 : 1428-35.
PubMed
Varadhachary GR, et al. Cancer of unknown primary site. N Engl J Med 2014 ; 371 : 757-65.
PubMed
Ross JS, et al. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site : New Routes to Targeted Therapies. JAMA Oncol 2015 ; 1 : 40-9.
PubMed
Conner JR, et al. Metastatic carcinoma of unknown primary : diagnostic approach using immunohistochemistry. Adv Anat Pathol 2015 ; 22 : 149-67.
PubMed
Bochtler T, et al. Diagnosis and management of metastatic neoplasms with unknown primary. Semin Diagn Pathol 2018 ; 35 : 199-206.
PubMed

3章 探索法の実際

P.12 掲載の参考文献
NCCN Guidelines for Occult Primary Version I. 2018.
 
日本臨床腫瘍学会. 原発不明がん診療ガイドライン 改訂第2版. 南江堂 ; 2018.
 
Burglin SA, et al. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary : A systematic review and meta-analysis. Medicine (Baltimore) 2017 ; 96 : e6713.
PubMed
Moller AK, et al. 18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site : a literature review. Oncologist 2011 ; 16 : 445-51.
 
Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors : systematic review and meta-analysis. Eur Radiol 2009 ; 19 : 731-44.
 
Breuer N, et al. Prognostic relevance of 18F-FDG PET/CT in carcinoma of unknown primary. Clin Nucl Med 2014 ; 39 : 131-5.
PubMed
Lee JR, et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors : comparison of 18F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Radiology 2015 ; 274 : 764-71.
PubMed
Godeny M, et al. Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis. Cancer Imaging 2016 ; 16 : 38.
PubMed
Koh DM, Collins DJ. Diffusion-weighted MRI in the body : applications and challenges in oncology. AJR 2007 ; 188 : 1622-35.
PubMed
Sekine T, et al. PET/MR Outperforms PET/CT in Suspected Occult Tumors. Clin Nucl Med 2017 ; 42 : e88-e95.
PubMed
P.25 掲載の参考文献
Parvin Ganjei-Azar, et al., Effusion Cytology. New York : Demos Medical Publishing ; 2011.
 
Gattuso P, et al., eds. Differential Diagnosis in Cytopathology. 2nd ed. Cambridge : Cambridge University Press ; 2014.
 
土屋眞一監. 体腔液細胞診カラーアトラス. 東京 : 文光堂 ; 2012.
 
P.30 掲載の参考文献
Losa F, et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol 2018 ; 20 : 1361-72.
PubMed
Conway AM, et al. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP) : taking the 'U' out of 'CUP'. Br J Cancer 2019 ; 120 : 141-53.
 
Binder C, et al. Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med 2018 ; 7 : 4814-24.
PubMed
Ramaswamy S, et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001 ; 98 : 15149-54.
PubMed
Tothill RW, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 2005 ; 65 : 4031-40.
PubMed
Horlings HM, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 2008 ; 26 : 4435-41.
PubMed
Varadhachary GR, et al. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol 2008 ; 9 : 596-9.
PubMed
van Laar RK, et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int J Cancer 2009 ; 125 : 1390-7.
PubMed
Greco FA, et al. Molecular profiling diagnosis in unknown primary cancer : accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013 ; 105 : 782-90.
PubMed
Tothill RW, et al. Development and validation of a gene expression tumour classifier for cancer of unknown primary. Pathology 2015 ; 47 : 7-12.
PubMed
Yoon HH, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus : NCCTG N0871 (alliance). Ann Oncol 2016 ; 27 : 339-44.
PubMed
Ma XJ, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 2006 ; 130 : 465-73.
PubMed
Weiss LM, et al. Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors. J Mol Diagn 2013 ; 15 : 263-9.
PubMed
Hainsworth JD, et al. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 2012 ; 11 : 112-8.
 
Hainsworth JD, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site : a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013 ; 31 : 217-23.
 
Harrandah AM, et al. Emerging microRNAs in cancer diagnosis, progression, and immune surveillance. Cancer Lett 2018 ; 438 : 126-32.
PubMed
Lu J, et al. MicroRNA expression profiles classify human cancers. Nature 2005 ; 435 : 834-8.
PubMed
Rosenfeld N, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008 ; 26 : 462-9.
PubMed
Rosenwald S, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010 ; 23 : 814-23.
PubMed
Varadhachary GR, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 2011 ; 17 : 4063-70.
PubMed
Ferracin M, et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol 2011 ; 225 : 43-53.
PubMed
Moran S, et al. Precision medicine based on epigenomics : the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol 2017 ; 14 : 682-94.
PubMed
Fernandez AF, et al. A DNA methylation fingerprint of 1628 human samples. Genome Res 2012 ; 22 : 407-19.
PubMed
Moran S, et al. Epigenetic profiling to classify cancer of unknown primary : a multicentre, retrospective analysis. Lancet Oncol 2016 ; 17 : 1386-95.
PubMed
Tothill RW, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol 2013 ; 231 : 413-23.
PubMed
Ross JS, et al. Comprehensive genomic profiling of carcinoma of unknown primary site : new routes to targeted therapies. JAMA Oncol 2015 ; 1 : 40-9.
PubMed
Gatalica Z, et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site : analysis of 1806 cases. Oncotarget 2014 ; 5 : 12440-7.
PubMed
Varghese AM, et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann Oncol 2017 ; 28 : 3015-21.
PubMed
Subbiah IM, et al. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience 2017 ; 4 : 47-56.
 
Loffler H, et al. Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget 2016 ; 7 : 44322-9.
PubMed
Gatalica Z, et al. Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. Eur J Cancer 2018 ; 94 : 179-86.
PubMed
Kato S, et al. Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary. Cancer Res 2017 ; 77 : 4238-46.
PubMed
Hoadley KA, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 2018 ; 173 : 291-304.
PubMed

4章 原発不明癌の背景 - 転移部位別の探索の実際

P.49 掲載の参考文献
Dail DH. Metastases to and from the lung. In : Tomashefski JF, et al., eds. Dail and Hammar's Pulmonary Pathology. New York : Springer ; 2008. p.735-66.
 
Aubry MC, Burke AP. Metastases to the lung and pleura. In : Burke AP, et al., eds. Practical Thoracic Pathology. Philadelphia : Wolters Kluwer ; 2017. p.441-7.
 
Pelosi G, et al. Metastases to the lung. In : Travis WD, et al., eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon : IARC Press ; 2015. p.148-51.
 
Murer B, et al. Metastases involving the lungs. In : Hasleton P, Flieder DB, eds. Spencer's Pathology of the Lung. 6th ed. Cambridge : Cambridge University Press ; 2013. p.1375-407.
 
湊宏. 肺転移性腫瘍の鑑別診断. 病理と臨床 2010 ; 28 : 239-46.
Medical*Online
日本臨床腫瘍学会監訳. 原発不明がん. NCCNガイドライン日本語版. https://www2.tri-kobe.org/nccn/guideline/occult/japanese/occult.pdf
 
Vidarsdottir H, et al. Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol 2018 ; 150 : 533-44.
PubMed
Troxell ML, et al. Comparison of estrogen and progesterone receptor antibody reagents using proficiency testing data. Arch Pathol Lab Med 2017 ; 141 : 1402-12.
PubMed
Riquet M, et al. Intrathoracic lymph node metastases from extrathoracic carcinoma : the place for surgery. Ann Thorac Surg 2009 ; 88 : 200-5.
PubMed
Chen ZM, et al. Differential expression of alpha-methylacyl coenzyme A racemase in adenocarcinomas of the small and large intestines. Am J Surg Pathol 2005 ; 29 : 890-6.
PubMed
P.62 掲載の参考文献
森永正二郎. 原発不明癌の病理診断における免疫染色の意義. 深山正久ほか編. 病理と臨床. 臨時増刊号 32. 免疫組織化学-診断と治療選択の指針. 東京 : 文光堂 ; 2014. p.64-75.
 
元井亨. 転移性骨腫瘍と上皮様骨腫瘍の鑑別. 野島孝之, 小田義直編. 腫瘍病理鑑別診断アトラス 骨腫瘍. 東京 : 文光堂 ; 2016. p.192-8.
 
吉田朗彦. 肉腫の転移をめぐって. 病理と臨床 2017 ; 35 : 167-71.
Medical*Online
Bullough PG. Malignant nonmatrix-producing bone tumors. In : Orthopaedic Pathology. 5th ed. Maryland Heights : Mosby ; 2010. p.477-96.
 
Unni KK, Inwards CY. Conditions that commonly simulate primary neoplasms of bone. In : Dahlin's Bone Tumors. 6th ed. Philadelphia : Wolters Kluwer ; 2010. p.305-80.
 
Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012 ; 379 : 1428-35.
PubMed
Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 2014 ; 371 : 757-65.
PubMed
Bocklage TJ, et al. Metastatic tumors of soft tissue and bone. In : Bone and Soft Tissue Tumors. A Multidisciplinary Review with Case Presentations. London : JP Medical Publishers ; 2014. p.343-65.
 
Reith JD. Bone and joints. In : Goldblum JR, et al., eds. Rosai and Ackerman's Surgical Pathology. 11th ed. Philadelphia : Elsevier ; 2018. p.1740-809.
 
P.73 掲載の参考文献
相島慎一, 山地康大郎. 転移性肝腫瘍の病理. 臨床外科 2016 ; 71 : 1331-7.
 
Fan Z, et al. Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma : 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 2003 ; 16 : 137-44.
PubMed
Baumhoer D, et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues. Am J Clin Pathol 2008 ; 129 : 899-906.
PubMed
Yang Z, et al. Immunohistochemical characterization of the origins of metastatic well-differentiated neuroendocrine tumors to the liver. Am J Surg Pathol 2017 ; 41 : 915-22.
 
P.80 掲載の参考文献
Johnson WC. Metastatic carcinoma of the skin. In : Elder DE, ed. Lever's Histopathology of the Skin. Philadelphia : Wolters Kluwer ; 2015. p.1417-28.
 
Patterson JW. Cutaneous metastasis. In : Weedon's Skin Pathology. London : Elsevier ; 2016. p.1118-28.
 
Mahalingam M, et al. The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin : an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol 2010 ; 23 : 713-9.
PubMed
Lee JJ, et al. p40 exhibits better specificity than p63 in distinguishing primary skin adnexal carcinomas from cutaneous metastases. Hum Pathol 2014 ; 45 : 1078-83.
PubMed
P.104 掲載の参考文献
日本頭頸部癌学会編. 頭頸部癌診療ガイドライン. 2018年版. 東京 : 金原出版 ; 2018.
 
日本臨床腫瘍学会編. 頭頸部がん薬物療法ガイダンス. 第2版. 東京 : 金原出版 ; 2018.
 
日本臨床腫瘍学会編. 原発不明がん診療ガイドライン. 改訂第2版. 東京 : 南江堂 ; 2018.
 
Stelow EB, French CA. Carcinomas of the upper aerodigestive tract with rearrangement of the nuclear protein of the testis (NUT) gene (NUT midline carcinomas). Adv Anat Pathol 2009 ; 16 : 92-6.
PubMed
P.112 掲載の参考文献
Travis WD, et al., eds. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Lyon : IARC Press ; 2015. p.183-298.
 
Bi Y, et al. Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin : A comparative study with their pulmonary counterparts. J Surg Oncol 2016 ; 114 : 697-702.
PubMed
Middleton G. Involvement of the thymus by metastic neoplasms. Br J Cancer 1966 ; 20 : 41-6.
PubMed
Nonaka D, et al. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms. Am J Surg Pathol 2007 ; 31 : 1038-44.
PubMed

5章 治療法の選択

P.128 掲載の参考文献
Fizazi K, et al. Cancers of unknown primary site : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015 ; 26 Suppl 5 : v133-8.
 
Merson M, et al. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 1992 ; 70 : 504-8.
PubMed
De Bresser J, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis : a systematic review. Eur J Surg Oncol 2010 ; 36 : 114-9.
PubMed
Varadarajan R, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 2006 ; 71 : 456-9.
PubMed
Galimberti V, et al. Clinical experience with axillary presentation breast cancer. Breast Cancer Res Treat 2004 ; 88 : 43-7.
PubMed
Black D, et al. Fallopian tube and peritoneal cancers. Raghavan D, et al., eds. Textbook of Uncommon Cancer. 4th ed. Wiley-Blackwell ; 2012. p.582-90.
 
Levanon K, et al. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008 ; 26 : 5284-93.
PubMed
Bloss JD, et al. Extraovarian peritoneal serous papillary carcinoma : a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993 ; 50 : 347-51.
PubMed
Ayhan A, et al. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma : is it different from that for ovarian serous papillary cancer? Int J Gynecol Cancer 2006 ; 16 : 484-9.
PubMed
Bloss JD, et al. Extraovarian peritoneal serous papillary carcinoma : a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 2003 ; 89 : 148-54.
 
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006 ; 12 : 6243s-6249s.
PubMed
Leung AK, et al. The clinical course of patients with prostate-specific antigen > 100 ng/ml : insight into a potential population for targeted prostate-specific antigen screening. Urology 2018 ; 117 : 101-7.
 
Gentile PS, et al. Disseminated prostatic carcinoma simulating primary lung cancer. Indications for immunodiagnostic studies. Cancer 1988 ; 62 : 711-5.
PubMed
Varadhachary GR, et al. Carcinoma of unknown primary with gastrointestinal profile : immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 2014 ; 19 : 479-84.
 
Stang A, et al. Gonadal and extragonadal germ cell tumours in the United States, 1973-2007. Int J Androl 2012 ; 35 : 616-25.
PubMed
Richardson RL, et al. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med 1981 ; 94 : 181-6.
PubMed
Bauer DE, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012 ; 18 : 5773-9.
PubMed
Union for International Cancer Control. Brierley JD, et al., eds. Head and Neck Tumours. 8th ed. Oxford ; John Wiley & Sons ; 2017. p.17-56.
 
Issing WJ, et al. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003 ; 260 : 436-43.
PubMed
Patel RS, et al. Squamous cell carcinoma from an unknown head and neck primary site : a "selective treatment" approach. Arch Otolaryngol Head Neck Surg 2007 ; 133 : 1282-7.
 
Aslani M, et al. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site : Is there a need for neck dissection? Head Neck 2007 ; 29 : 585-90.
 
Strojan P, et al. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes : role of elective irradiation. Eur Arch Otorhinolaryngol 2016 ; 273 : 4561-9.
PubMed
Lou J, et al. Squamous cell carcinoma of cervical lymph nodes from an unknown primary site : the impact of neck dissection. J Cancer Res Ther 2015 ; 11 Suppl 2 : C161-7.
 
Shehadeh NJ, et al. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head Neck 2006 ; 28 : 1090-8.
PubMed
Eldeeb H, Hamed RH. Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin : the impact of chemoradiotherapy. Chin J Cancer 2012 ; 31 : 484-90.
PubMed
Zaren HA, Copeland EM 3rd. Inguinal node metastases. Cancer 1978 ; 41 : 919-23.
PubMed
Guarischi A, et al. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 1987 ; 59 : 572-7.
PubMed
Joseph K, et al. Carcinoma of unknown primary in the inguinal lymph node region of squamous cell origin : a case series. Pract Radiat Oncol 2014 ; 4 : 404-8.
PubMed
Scoazec JY, et al. Professional practices and diagnostic issues in neuroendocrine tumour pathology : results of a prospective one-year survey among French pathologists (the PRONET study). Neuroendocrinology 2017 ; 105 : 67-76.
PubMed
Bergsland EK, Nakakura EK. Neuroendocrine tumors of unknown primary : Is the primary site really not known? JAMA Surg 2014 ; 149 : 889-90.
PubMed
Kvols LK, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986 ; 315 : 663-6.
PubMed
Rinke A, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63.
 
Caplin ME, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33.
PubMed
Yao JC, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77.
 
Raymond E, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13.
PubMed
Wong MH, et al. Systematic review and meta-analysis on the role of chemotherapy in advanced and metastatic neuroendocrine tumor (NET). PLoS One 2016 ; 11 : e0158140.
PubMed
Dasari A, et al. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas : a SEER database analysis of 162,983 cases. Cancer 2018 ; 124 : 807-15.
PubMed
Mitry E, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999 ; 81 : 1351-5.
PubMed
Hainsworth JD, et al. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : a Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006 ; 24 : 3548-54.
PubMed
Nakano K, et al. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 2012 ; 42 : 697-703.
PubMed
Zuur CL, et al. Diagnosis and treatment of isolated neck metastases of adenocarcinomas. Eur J Surg Oncol 2002 ; 28 : 147-52.
PubMed
Nguyen LN, et al. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 1998 ; 83 : 2181-4.
PubMed
Lee J, et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary : a systematic review and meta-analysis. Br J Cancer 2013 ; 108 : 39-48.
PubMed
Hainswoth JD, et al. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site : results of a 12-year experience. J Clin Oncol 1992 ; 10 : 912-22.
 
Hess KR, et al. Classification and regression tree analysis of 1,000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 1999 ; 5 : 3403-10.
 
Culine S, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002 ; 20 : 4679-83.
 
Kodaira M, et al. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy. Ann Oncol 2010 ; 21 : 1163-7.
PubMed
Hainsworth JD, Greco FA. Gene expression profiling in patients with carcinoma of unknown primary site : from translational research to standard of care. Virchows Arch 2014 ; 464 : 393-402.
PubMed
Moran S, et al. Epigenetic profiling to classify cancer of unknown primary : a multicentre, retrospective analysis. Lancet Oncol 2016 ; 17 : 1386-95.
PubMed
Hasegawa H, et al. Site-specific chemotherapy based on predicted primary site by pathological profile for carcinoma of unknown primary site. Clin Oncol 2018 ; 30 : 667-73.
PubMed
Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 2014 ; 371 : 757-65.
PubMed
NICE (National Institute for Health and Care Excellence) guidance. Metastatic malignant disease of unknown primary origin in adults : diagnosis and management. 2010. https://www.nice.org.uk/guidance/CG104
 
Abbruzzese JL, et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995 ; 13 : 2094-103.
PubMed

6章 症例提示

P.142 掲載の参考文献
Pavlidis N, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003 ; 39 : 1990-2005.
PubMed
Euscher ED, et al. Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy. Am J Surg Pathol 2004 ; 28 : 1217-23.
PubMed
Visvanathan K, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features : A reproducibility study. Am J Surg Pathol 2011 ; 35 : 1766-75.
PubMed
Ledermann JA, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow?up. Ann Oncol 2013 ; 24 (Suppl 6) : v24-32.
 
P.148 掲載の参考文献
Kubonishi I, et al. Novel (t 15;19) (q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 1991 ; 51 : 3327-8.
 
French CA. NUT midline carcinoma. Cancer Genet Cytogenet 2010 ; 203 : 16-20.
PubMed
Stelow EB, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol 2008 ; 32 : 828-34.
PubMed
田中水緒, 田中祐吉. NUT midline carcinoma. 深山正久ほか編. 腫瘍病理鑑別診断アトラス 縦隔腫瘍・胸膜腫瘍. 東京 : 文光堂 ; 2014.
 
French CA. The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 2013 ; 7 : 11-6.
PubMed
P.152 掲載の参考文献
Yasuoka H, et al. A rare case of ectopic papillary thyroid carcinoma transformed into squamous cell carcinoma. Pathol Int 2018 ; 68 : 246-50.
PubMed
Rosai J, et al. Thyroid tumors with clear cell, squamous, and mucinous features. In : Silverberg SG, et al., eds. Tumors of the Thyroid and Parathyroid Glands. Maryland : American Registry of Pathology ; 2014. p.221-39.
 
西阪隆ほか. 扁平上皮癌とその特殊型. 深山正久ほか編. 腫瘍病理鑑別診断アトラス 肺癌. 東京 : 文光堂 ; 2014. p.45-55.
 
廣川満良. 扁平上皮化生とモルラ. 坂本穆彦ほか編. 腫瘍病理鑑別診断アトラス 甲状腺癌. 東京 : 文光堂 ; 2011. p.133-42.
 
Laury AR, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011 ; 35 : 816-26.
PubMed
P.157 掲載の参考文献
Grignon DJ, et al. Glandular neoplasms. In : Moch H, et al., eds. WHO Classification of Tumours of the urinary system and male genital organs. 4th ed. Lyon : IARC Press ; 2016. p.111-2.
 
Vasudevan G, et al. Bladder adenocarcinoma : a persisting diagnostic dilemma. J Clin Diagn Res 2017 ; 11 : ER01-ER04.
PubMed
Wang HL, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol 2001 ; 25 : 1380-7.
PubMed
Rao Q, et al. Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma : extended immunohistochemical profiles emphasizing novel markers. Mod Pathol 2013 ; 26 : 725-32.
PubMed
Lin F, et al. Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas. Appl Immunohistochem Mol Morphol 2004 ; 12 : 153-9.
PubMed
Sun K, et al. Clear cell adenocarcinoma of urinary bladder and urethra. Arch Pathol Lab Med 2008 ; 132 : 1417-22.
PubMed
P.168 掲載の参考文献
Inoguchi N, et al. Expression of prostate-specific antigen and androgen receptor in extramammary Paget's disease and carcinoma. Clin Exp Dermatol 2007 ; 32 : 91-4.
PubMed
Hammer A, et al. Prostate-specific antigen-positive extramammary Paget's disease-association with prostate cancer. APMIS 2008 ; 116 : 81-8.
PubMed
Oji M, et al. Serum carcinoembryonic antigen level in Paget's disease. Br J Dermatol 1984 ; 110 : 211-3.
PubMed
Kacerovska D, et al. Extramammary Paget disease. In : Elder DE, et al., eds. WHO Classification of Skin Tumours. 4th ed. Lyon : IARC Press ; 2018. p.217-8.
 
Elgamal AA, et al. Detection of prostate specific antigen in pancreas and salivary glands : a potential impact on prostate cancer overestimation. J Urol 1996 ; 156 : 464-8
 
Bodey B, et al. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. Anticancer Res 1997 ; 17 : 2577-81.
PubMed

書評

最近チェックした商品履歴

Loading...